Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (VYGR)
NASDAQ:VYGR
VYGR Stock Chart & Stats
$3.76
-$0.14(-2.36%)
At close: 4:00 PM EST
$3.76
-$0.14(-2.36%)
Day’s Range― - ―
52-Week Range$2.65 - $5.96
Previous CloseN/A
Volume91.62K
Average Volume (3M)449.64K
Market Cap
$209.06M
Enterprise Value$104.05M
Total Cash (Recent Filing)$208.93M
Total Debt (Recent Filing)$38.37M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Mar 10, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding55,600,082
10 Day Avg. Volume630,530
30 Day Avg. Volume449,643
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.09
Price to Sales (P/S)4.09
P/FCF Ratio-17.36
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit3.32
Enterprise Value/Ebitda-0.78
Forecast
1Y Price Target
$13.20Price Target Upside251.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.6
Revenue Forecast (FY)$60.16M
Bulls Say, Bears Say
Bulls Say
Clinical Data ReadoutsInitial PET imaging data from the MAD portion of the VY7523 early-phase study could demonstrate brain target engagement in Alzheimer's patients and materially influence trial expectations.
Financial Stability And RunwayA strong cash position and management guidance for a runway into 2028 supports continued development plans and lowers the likelihood of near-term financing pressure.
Strategic Collaboration And Modality ExpansionCollaboration with Transition Bio to discover small molecules targeting TDP‑43 expands therapeutic modalities beyond gene and antibody approaches, improving chances of finding effective treatments for ALS and FTD.
Bears Say
Analyst Valuation ImpactRemoval of the anti‑Aβ vectorized program from analyst models has prompted price target reductions, indicating potential downside to current valuations if programs are scaled back.
Class-wide SkepticismFailure of a peer tau antibody program and limited public data have intensified skepticism among key opinion leaders, which could pressure investor sentiment toward tau-targeting assets.
Pipeline Reprioritization RiskDeprioritization of SOD1‑ALS and anti‑Aβ gene therapy programs suggests a strategic shift that may reduce near-term clinical milestones and slow the pace of visible progress.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $2.65 and its highest was $5.96 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $209.06M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 50 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.521 by $0.051.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.51.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 55,600,082 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.521. Following the earnings report the stock price went up 0.709%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.20 (251.06% Upside)
$13.20 (251.06% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 706.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.69%
12-Months-Change
Fundamentals
Return on Equity
-46.09%
Trailing 12-Months
Asset Growth
-32.33%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
VYGR Stock 12 Month Forecast
Average Price Target
$13.20
▲(251.06% Upside)
Technical Analysis
Galectin Therapeutics
―
Cartesian Therapeutics
―
Silence Therapeutics
―
Tenaya Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
2.23% Insiders
11.62% Mutual Funds
0.35% Other Institutional Investors
76.00% Public Companies and
Individual Investors